Open AccessEffectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome
Author(s) -
Sadettin Uslu
Publication year - 2020
Publication title -
european journal of case reports in internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2284-2594
DOI - 10.12890/2020_001731
Subject(s) - tocilizumab , medicine , cytokine release syndrome , covid-19 , interleukin 6 , cytokine , cytokine storm , disease , immunology , virology , infectious disease (medical specialty) , outbreak
Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections. CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis. Tocilizumab (TCZ), an interleukin‐6 (IL-6) inhibitor, may ameliorate the CRS associated with severe COVID‐19 and thus improve clinical outcomes. We present a case of life-threatening CRS caused by COVID-19 infection successfully treated with TCZ.